{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:41:27Z","timestamp":1694641287498},"posted":{"date-parts":[[2023,6,6]]},"group-title":"In Review","reference-count":38,"publisher":"Research Square Platform LLC","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,5,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p><jats:bold>Purpose:: <\/jats:bold>Multiple myeloma(MM) is a common malignant tumor in the blood system. Despite recent advances in its treatment, its symptomatic remission rate and survival rate are still not optimistic. In the future, it is necessary to continue to search for different treatment targets and new treatment methods in order to improve the quality of life and survival time of patients with MM. The study aims to explore the potential immune related pivotal genes and immune infiltration patterns in MM.\n<jats:bold>Methods: <\/jats:bold>The study included peripheral blood samples from patients with MM who our hospital from October 2020 to April 2022. Obtain a gene chip for research from a comprehensive gene expression database, perform differential expression analysis on the processed gene dataset, and then perform functional enrichment analysis, weighted gene co expression network analysis, GSEA immune infiltration analysis, and LASSO regression analysis on the obtained differential expression genes to obtain the hub genes. Finally, the hub gene TNFSF14 (LIGHT) was validated by qRT-PCR.\n<jats:bold>Results: <\/jats:bold>In the study, three immune-related hub genes (ADAM8, CR2, and TNFSF14) and three main types of peripheral immune cells (activated CD8 T cells, macrophages, and plasma cell like dendritic cells) were obtained, which are closely related to the pathogenesis of MM. Then, by collecting peripheral blood samples from some patients in our hospital and conducting real-time fluorescence quantitative polymerase chain reaction, it was confirmed that the hub gene TNFSF14 (LIGHT) mined in this study was highly expressed in peripheral blood samples from patients with MM, which may indicate that it plays a pathogenic role in MM.\n<jats:bold>Conclusion: <\/jats:bold>The study found that immune-related hub genes (ADAM8, CR2, and TNFSF14) are closely related to the pathogenesis of MM, and should be further researched.<\/jats:p>","DOI":"10.21203\/rs.3.rs-2981597\/v1","type":"posted-content","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T23:04:40Z","timestamp":1686092680000},"source":"Crossref","is-referenced-by-count":0,"title":["Identification of Immune-Related Hub Genes in Multiple Myeloma"],"prefix":"10.21203","author":[{"given":"Xinge","family":"Sheng","sequence":"first","affiliation":[{"name":"Zhongshan Hospital Xiamen University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuli","family":"Hong","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital Xiamen University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyuan","family":"Lu","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital Xiamen University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangfang","family":"Huang","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital Xiamen University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilan","family":"Deng","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital Xiamen University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanyi","family":"Lu","sequence":"additional","affiliation":[{"name":"Zhongshan Hospital Xiamen University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8761","reference":[{"key":"ref1","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","author":"Rajkumar SV","unstructured":"Rajkumar S. V., Dimopoulos M. A., Palumbo A., et al.International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.Lancet Oncol.2014;15;e538-48.","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle RA","year":"2002","unstructured":"Kyle R. A., Therneau T. M., Rajkumar S. V., et al.A long-term study of prognosis in monoclonal gammopathy of undetermined significance.N Engl J Med.2002;346;564\u20139.","journal-title":"N Engl J Med"},{"key":"ref3","article-title":"V.Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)","author":"Kyle RA","year":"2011","unstructured":"Kyle R. A. and Rajkumar S. V.Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).Oncology (Williston Park).2011;25;578 \u2013 86.","journal-title":"Oncology (Williston Park)"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp PR","year":"2005","unstructured":"Greipp P. R., San Miguel J., Durie B. G., et al.International staging system for multiple myeloma.J Clin Oncol.2005;23;3412\u201320.","journal-title":"J Clin Oncol"},{"key":"ref5","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","author":"Stewart AK","unstructured":"Stewart A. K., Rajkumar S. V., Dimopoulos M. A., et al.Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.N Engl J Med.2015;372;142 \u2013 52.","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"A.The Tumor Microenvironment Innately Modulates Cancer Progression","volume":"79","author":"Hinshaw DC","year":"2019","unstructured":"Hinshaw D. C. and Shevde L. A.The Tumor Microenvironment Innately Modulates Cancer Progression.Cancer Res.2019;79;4557\u20134566.","journal-title":"Cancer Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cac2.12178","article-title":"Advancing to the era of cancer immunotherapy","volume":"41","author":"Wang Y","year":"2021","unstructured":"Wang Y., Wang M., Wu H. X., et al.Advancing to the era of cancer immunotherapy.Cancer Commun (Lond).2021;41;803\u2013829.","journal-title":"Cancer Commun (Lond)"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The Next Decade of Immune Checkpoint Therapy","volume":"11","author":"Sharma P","year":"2021","unstructured":"Sharma P., Siddiqui B. A., Anandhan S., et al.The Next Decade of Immune Checkpoint Therapy.Cancer Discov.2021;11;838\u2013857.","journal-title":"Cancer Discov"},{"key":"ref9","article-title":"Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma","author":"Favaloro J","unstructured":"Favaloro J., Liyadipitiya T., Brown R., et al.Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma.Leuk Lymphoma.2014;55;2893 \u2013 900.","journal-title":"Leuk Lymphoma"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"806","DOI":"10.2174\/1568009617666170214102301","article-title":"Multiple Myeloma and the Immune Microenvironment","volume":"17","author":"Kawano Y","year":"2017","unstructured":"Kawano Y., Roccaro A. M., Ghobrial I. M., et al.Multiple Myeloma and the Immune Microenvironment.Curr Cancer Drug Targets.2017;17;806\u2013818.","journal-title":"Curr Cancer Drug Targets"},{"key":"ref11","author":"G\u00f6rg\u00fcn GT","year":"2013","unstructured":"G\u00f6rg\u00fcn G. T., Whitehill G., Anderson J. L., et al.Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.Blood.2013;121;2975-87."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian A","year":"2005","unstructured":"Subramanian A., Tamayo P., Mootha V. K., et al.Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.Proc Natl Acad Sci U S A.2005;102;15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade","volume":"18","author":"Charoentong P","year":"2017","unstructured":"Charoentong P., Finotello F., Angelova M., et al.Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.Cell Rep.2017;18;248\u2013262.","journal-title":"Cell Rep"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian D","year":"2016","unstructured":"Kazandjian D.Multiple myeloma epidemiology and survival: A unique malignancy.Semin Oncol.2016;43;676\u2013681.","journal-title":"Semin Oncol"},{"key":"ref15","author":"Shah UA","unstructured":"Shah U. A. and Mailankody S.Emerging immunotherapies in multiple myeloma.Bmj.2020;370;m3176."},{"key":"ref16","article-title":"Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma","author":"Swamydas M","unstructured":"Swamydas M., Murphy E. V., Ignatz-Hoover J. J., et al.Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma.J Hematol Oncol.2022;15;17.","journal-title":"J Hematol Oncol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.joca.2017.02.791","article-title":"ADAM metalloproteinases in osteoarthritis - looking beyond the 'usual suspects'","volume":"25","author":"Yang CY","year":"2017","unstructured":"Yang C. Y., Chanalaris A. and Troeberg L.ADAMTS and ADAM metalloproteinases in osteoarthritis - looking beyond the 'usual suspects'.Osteoarthritis Cartilage.2017;25;1000\u20131009.","journal-title":"Osteoarthritis Cartilage"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"8053","DOI":"10.4049\/jimmunol.178.12.8053","article-title":"Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding","volume":"178","author":"G\u00f3mez-Gaviro M","year":"2007","unstructured":"G\u00f3mez-Gaviro M., Dom\u00ednguez-Luis M., Canchado J., et al.Expression and regulation of the metalloproteinase ADAM-8 during human neutrophil pathophysiological activation and its catalytic activity on L-selectin shedding.J Immunol.2007;178;8053\u201363.","journal-title":"J Immunol"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11020113","article-title":"Cohort Analysis of ADAM8 Expression in the PDAC Tumor Stroma","volume":"11","author":"Jaworek C","year":"2021","unstructured":"Jaworek C., Verel-Yilmaz Y., Driesch S., et al.Cohort Analysis of ADAM8 Expression in the PDAC Tumor Stroma.J Pers Med.2021;11;","journal-title":"J Pers Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/art.24753","article-title":"ADAM-8 isolated from human osteoarthritic chondrocytes cleaves fibronectin at Ala(271)","volume":"60","author":"Zack MD","year":"2009","unstructured":"Zack M. D., Malfait A. M., Skepner A. P., et al.ADAM-8 isolated from human osteoarthritic chondrocytes cleaves fibronectin at Ala(271).Arthritis Rheum.2009;60;2704\u201313.","journal-title":"Arthritis Rheum"},{"key":"ref21","article-title":"Involvement of a disintegrin and a metalloproteinase 8 (ADAM8) in osteoclastogenesis and pathological bone destruction","author":"Ainola M","unstructured":"Ainola M., Li T. F., Mandelin J., et al.Involvement of a disintegrin and a metalloproteinase 8 (ADAM8) in osteoclastogenesis and pathological bone destruction.Ann Rheum Dis.2009;68;427 \u2013 34.","journal-title":"Ann Rheum Dis"},{"key":"ref22","article-title":"D.ADAM8: a novel osteoclast stimulating factor","author":"Choi SJ","unstructured":"Choi S. J., Han J. H. and Roodman G. D.ADAM8: a novel osteoclast stimulating factor.J Bone Miner Res.2001;16;814 \u2013 22.","journal-title":"J Bone Miner Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"112s-117s","DOI":"10.1111\/1523-1747.ep12876069","article-title":"CR2 complement receptor","volume":"94","author":"Cooper NR","year":"1990","unstructured":"Cooper N. R., Bradt B. M., Rhim J. S., et al.CR2 complement receptor.J Invest Dermatol.1990;94;112s-117s.","journal-title":"J Invest Dermatol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ni1113","article-title":"C.The complement system in regulation of adaptive immunity","volume":"5","author":"Carroll M","year":"2004","unstructured":"Carroll M. C.The complement system in regulation of adaptive immunity.Nat Immunol.2004;5;981\u20136.","journal-title":"Nat Immunol"},{"key":"ref25","article-title":"CD21(-\/low) B cells associate with joint damage in rheumatoid arthritis patients","author":"Thorarinsdottir K","unstructured":"Thorarinsdottir K., Camponeschi A., Jonsson C., et al.CD21(-\/low) B cells associate with joint damage in rheumatoid arthritis patients.Scand J Immunol.2019;90;e12792.","journal-title":"Scand J Immunol"},{"key":"ref26","article-title":"A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis","author":"Nichols EM","unstructured":"Nichols E. M., Jones R., Watson R., et al.A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.Oncotarget.2015;6;32669-80."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI200113827","article-title":"The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT","volume":"108","author":"Wang J","year":"2001","unstructured":"Wang J., Lo J. C., Foster A., et al.The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT.J Clin Invest.2001;108;1771\u201380.","journal-title":"J Clin Invest"},{"key":"ref28","author":"Brunetti G","year":"2014","unstructured":"Brunetti G., Rizzi R., Oranger A., et al.LIGHT\/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease.Oncotarget.2014;5;12950-67."},{"key":"ref29","article-title":"LIGHT\/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens","author":"Brunetti G","unstructured":"Brunetti G., Rizzi R., Storlino G., et al.LIGHT\/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens.Front Immunol.2018;9;2459.","journal-title":"Front Immunol"},{"key":"ref30","article-title":"J.CD8(+) T cells: foot soldiers of the immune system","author":"Zhang N","unstructured":"Zhang N. and Bevan M. J.CD8(+) T cells: foot soldiers of the immune system.Immunity.2011;35;161-8."},{"key":"ref31","author":"Lee JS","year":"2019","unstructured":"Lee J. S. and Ruppin E.Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1.JAMA Oncol.2019;5;1614\u20131618."},{"key":"ref32","author":"Guillerey C","year":"2018","unstructured":"Guillerey C., Harjunp\u00e4\u00e4 H., Carri\u00e9 N., et al.TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma.Blood.2018;132;1689\u20131694."},{"key":"ref33","article-title":"R.Monocyte and macrophage heterogeneity","author":"Gordon S","unstructured":"Gordon S. and Taylor P. R.Monocyte and macrophage heterogeneity.Nat Rev Immunol.2005;5;953 \u2013 64.","journal-title":"Nat Rev Immunol"},{"key":"ref34","article-title":"The Macrophage-Osteoclast Axis in Osteoimmunity and Osteo-Related Diseases","author":"Yao Y","unstructured":"Yao Y., Cai X., Ren F., et al.The Macrophage-Osteoclast Axis in Osteoimmunity and Osteo-Related Diseases.Front Immunol.2021;12;664871.","journal-title":"Front Immunol"},{"key":"ref35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176001","article-title":"Learning from Monocyte-Macrophage Fusion and Multinucleation: Potential Therapeutic Targets for Osteoporosis and Rheumatoid Arthritis","volume":"21","author":"Gambari L","year":"2020","unstructured":"Gambari L., Grassi F., Roseti L., et al.Learning from Monocyte-Macrophage Fusion and Multinucleation: Potential Therapeutic Targets for Osteoporosis and Rheumatoid Arthritis.Int J Mol Sci.2020;21;","journal-title":"Int J Mol Sci"},{"key":"ref36","article-title":"Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis","author":"Zheng Y","unstructured":"Zheng Y., Cai Z., Wang S., et al.Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.Blood.2009;114;3625-8."},{"key":"ref37","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","author":"Chauhan D","unstructured":"Chauhan D., Singh A. V., Brahmandam M., et al.Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.Cancer Cell.2009;16;309 \u2013 23.","journal-title":"Cancer Cell"},{"key":"ref38","author":"Ray A","year":"2014","unstructured":"Ray A., Tian Z., Das D. S., et al.A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.Leukemia.2014;28;1716-24."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2981597\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2981597\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T07:59:44Z","timestamp":1694505584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-2981597\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":38,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-2981597\/v1","relation":{},"subject":[],"published":{"date-parts":[[2023,6,6]]},"subtype":"preprint"}}